Omalizumab for Idiopathic Nonhistaminergic Angioedema: Evidence for Efficacy in 2 Patients

Figure 1

Time course of omalizumab’s effect on AE-QoL score in the two patients (clear and black squares) with InH-AAE. Both patients showed a rapid response to omalizumab and during the 6-month treatment the patients were free of AE attacks. Two months after suspension one patient (black squares) had symptom recurrences and therefore was retreated with omalizumab.